Skip to main content
OpenTrials
Completed

NCT Number: NCT07668076

The Potential Cardioprotective Effect of Addition of Atorvastatin in Breast Cancer Patients

the study aims to evaluate the cardioprotective effect of atorvastatin in breast cancer female patients treated with doxorubicin based chemotherapy

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Damanhour university

Beheira, Damanhour, 22511, Egypt

About this study

female patients with newly diagnosed breast cancer, who are candidates for AC protocol will be recruited from Damanhour oncology center.

All enrolled patients will be randomly assigned into 2 arms:

  • Control arm : will receive AC regimen only (doxorubicin 60 mg/m² IV + cyclophosphamide 600 mg/m² IV) for 4 cycles every 21 days.
  • Atorvastatin arm : will receive AC regimen mentioned above + atorvastatin 40 mg orally once daily for 3 months.

All patients will be submitted to:

  • Full patient history and clinical examination.
  • Routine follow up before and after each chemotherapy cycle (complete blood picture, liver function tests, renal function tests).
  • Echocardiography also will be obtained at the time of admission.
  • Serum samples will be collected from patients at the time of admission for measuring the cardiac biomarkers in addition to serum cholesterol level.

All patients will be followed up during 3 months' period. At the end of 3 months, Serum samples will be collected from patients for measuring the biomarkers. Statistical tests appropriate to the study design will be conducted to evaluate the significance of the results. 8. Measuring outcome: The primary outcome is the change of serum levels of the measured cardiac biomarkers after 4 cycles of AC regimen.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women with newly diagnosed breast cancer and ≥ 18 years old.
  • Naive to chemotherapy.
  • Left ventricular ejection fraction (LVEF) > 55%.

Exclusion criteria

  • Concurrent administration of any other cholesterol-lowering therapy.
  • Evidence of hepatic dysfunction (alanine aminotransferase level more than three times the upper limit of the normal range)
  • Evidence of renal dysfunction (creatinine level more than three times the upper limit of the normal range).
  • Predisposing factors for rhabdomyolysis, including hypothyroidism, reduced renal function, any muscle or liver disease.
  • Concurrent administration of potent CYP3A4-inhibitors.
  • Pregnancy or breast-feeding

Treatment and study plan

atorvastatin

Drug

atorvastatin 40 mg orally once daily for 3 months.

Primary outcomes

  1. cardiac biomarkers (NT-Pro BNP, ST2 and MPO)

    Time frame: baseline and 3 months ( after completion of 4 cycles of AC chemotherapy)

    change from baseline in Serum levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), suppression of tumorigenicity-2 (ST2), myeloperoxidase (MPO), and cholesterol using enzyme-linked immunosorbent assay (ELISA) kits and standard biochemical methods according to manufacturer instructions

Sponsors and collaborators

Lead sponsor

Damanhour University

Other

Registry information

Official study title

The Potential Cardioprotective Effect of Addition of Atorvastatin in Breast Cancer Patients Treated With Doxorubicin-based Chemotherapy

Important dates

Study start
2022
Primary completion
2024
Study completion
2024
First posted
Jun 25, 2026
Registry last updated
Jun 25, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.